Relmada Therapeutics demonstrated significant progress in Phase II trials for NDV-01, added promising new product candidates, and improved cash management. However, challenges remain with a decreased cash balance and a notable net loss. Despite these challenges, the advancements in clinical trials and strategic team expansions paint a positive outlook.

Company Guidance

During the Relmada Therapeutics Second Quarter 2025 Earnings Conference Call, the company provided guidance on its recent progress, financial status, and future plans. Relmada reported a $20.6 million cash balance as of June 30, 2025, down from $44.9 million at the end of 2024, with cash used in operations decreasing to $6.4 million from $13.3 million in the prior year. Research and development expenses fell to $2.8 million due to the wind-down of clinical trials for REL-1017, offset by ramp-up activities for NDV-01 and sepranolone. The net loss for the quarter was $9.9 million, or $0.30 per share, compared to $17.8 million, or $0.59 per share, in the same period of 2024. The company highlighted its focus on advancing NDV-01 for non-muscle invasive bladder cancer, with plans to initiate a Phase III study in the first half of 2026, and sepranolone for Prader-Willi syndrome, with a Phase II study also expected to begin in 2026.

Successful Phase II Results for NDV-01

The Phase II study for NDV-01 showed a 91% complete response rate in patients with high-grade non-muscle invasive bladder cancer, with no treatment-related adverse events greater than grade 3.

New Product Candidates

Relmada added two promising candidates: NDV-01 for bladder cancer and sepranolone for compulsivity disorders, addressing significant and underserved markets.

Cash Management and Financial Health

Relmada has a cash balance of $20.6 million at the end of Q2 2025, with a significant reduction in cash used in operations compared to the previous year, indicating improved cash management.

Expanded Team with Key Experts

Relmada expanded its team with two experts in bladder cancer and urologic oncology, Dr. Raj Pruthi and Dr. Yair Lotan, to support its clinical advisory board.

Relmada Therapeutics (RLMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RLMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.45 / -	-0.72	―	―	―
Aug 07, 2025	2025 (Q2)	-0.46 / -0.30	-0.59	49.15% (+0.29)	―
May 12, 2025	2025 (Q1)	-0.48 / -0.58	-0.72	19.44% (+0.14)	―
Mar 27, 2025	2024 (Q4)	-0.67 / -0.62	-0.84	26.19% (+0.22)	―
Nov 07, 2024	2024 (Q3)	-0.68 / -0.72	-0.73	1.37% (+0.01)	―
Aug 07, 2024	2024 (Q2)	-0.83 / -0.59	-0.84	29.76% (+0.25)	―
May 08, 2024	2024 (Q1)	-0.85 / -0.72	-0.87	17.24% (+0.15)	―
Mar 19, 2024	2023 (Q4)	-0.83 / -0.84	-1.28	34.38% (+0.44)	―
Nov 08, 2023	2023 (Q3)	-0.91 / -0.73	-1.31	44.27% (+0.58)	―
Aug 08, 2023	2023 (Q2)	-0.90 / -0.84	-1.33	36.84% (+0.49)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RLMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.60	$0.59	-1.67%
May 12, 2025	$0.40	$0.39	-2.50%
Mar 27, 2025	$0.30	$0.30	0.00%
Nov 07, 2024	$3.26	$3.28	+0.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Relmada Therapeutics (RLMD) report earnings?

Relmada Therapeutics (RLMD) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Relmada Therapeutics (RLMD) earnings time?

Relmada Therapeutics (RLMD) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RLMD EPS forecast?

RLMD EPS forecast for the fiscal quarter 2025 (Q3) is -0.45.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing